Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Aug 5;54(1):2213–2221. doi: 10.1080/07853890.2022.2107233

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 3. — Patients with detectable HBV DNA before liver transplantation had a higher prevalence of extended OLT criteria, and extended OLT criteria had a higher prevalence of recurrence than Milan criteria. (A) There were 26% (n = 19), 33.3% (n = 4), 55.0% (n = 11), and 66.7% (n = 8) preoperative detectable HBV DNA patients in Milan, beyond Milan within “Up-to-seven” out of “Up-to-seven” within Hangzhou, and beyond Hangzhou criteria, respectively (p=.011). (B) The prevalence of HCC recurrence was 4.1% (n = 3), 18.2% (n = 2), 42.9% (n = 9), and 83.3% (n = 10) that was significantly different between patients with Milan criteria, beyond Milan and within “Up-to-seven” beyond “Up-to-seven” and within Hangzhou, and beyond Hangzhou criteria, respectively (p<.001). *Beyond HZ: Beyond Hangzhou criteria. HBV DNA pos: HBV DNA detectable; HBV DNA neg: HBV DNA undetectable.